News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Certara Corporation’s New Muse Invent Allows Chemistry Researchers To Design Drug Candidates That Are Synthetically Feasible


8/11/2014 8:19:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ST. LOUIS--(BUSINESS WIRE)--Certara®, the leading global technology-enabled drug development and drug safety consultancy, announced today that its Muse molecular design workflow for the identification and optimization of lead drug candidates now has virtual synthetic chemistry capabilities. Known as Muse® Invent, this new product will enable researchers to create drug candidates with novel structures, scaffolds, or side-chains that meet multiple design objectives and are synthetically accessible. It will also describe the necessary synthesis pathway to create them.

“Muse has always been a popular product because it permits ‘outside of the box’ chemistry thinking; it allows customers to generate new chemical ideas without being limited to molecules found in existing databases and product catalogs,” said Certara Chief Technology Officer Jonathan Feldmann. “But when customers became enamored with the new molecules they created in Muse, they wanted to know how to make them in the lab.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES